Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR-IMHA Inclusive Research Excellence Prizes - Research Impact

University of Toronto

$25,000.00

Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 Pandemic and other extenuating circumstances: The CONSERVE 2021 Statement

EF 2022-23

Résumé
Rigorous design and transparent reporting of randomized trials and trial protocols are key enablers of open science. Trials can face unavoidable modifications due to new safety or efficacy information, regulatory revisions, changes in the standard of care, and more. Modifications can prompt methodological, ethical, feasibility, and analytical challenges that threaten open science. The COVID pandemic disrupted thousands of trials involving millions of participants. Scientists had no guidance on how to interpret and report those disruptions. CONSERVE (CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances) aims to improve the reporting of trials and trial protocols that undergo important modifications in response to extenuating circumstances. CONSERVE was developed using open science principles, led by a global panel of 37 trial investigators, methodologists, patient representatives, ethicists, funders, regulators, and journal editors. Our protocol was published on the Open Science Framework, involving a literature review, consensus-based panelist meetings using a modified Delphi process, and a global survey of trial stakeholders. The literature review yielded 38 relevant documents, but no generalizable guidance for reporting unanticipated modifications to trials and protocols. The panel used these findings to develop a consensus guideline. The global survey drew 198 respondents in 34 countries, of whom 90% understood the concept definitions and 85.4% could use the implementation tool. Feedback from survey respondents was used to finalize the guideline. CONSERVE was immediately publicly available in June 2021 through JAMA and the EQUATOR Network. CONSERVE offers tools and checklists to support transparent and rigorous reporting when trials and trial protocols face important modifications to the intended study. The panel is investigating the impacts of the CONSERVE 2021 Statement and the quality of trial reporting during the COVID pandemic.
Programme
CIHR-IMHA Inclusive Research Excellence Prizes - Research Impact
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
485089
Name
Orkin Aaron M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Other : CIHR-IMHA Inclusive Research Excellence Prizes
Projecttitle
Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 Pandemic and other extenuating circumstances: The CONSERVE 2021 Statement
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
CIHR-IMHA Inclusive Research Excellence Prizes - Research Impact
Keyworddelim
Covid-19; Delphi Studies; Open Science; Randomized Clinical Trials And Trial Protocols; Randomized Trial Methods; Randomized Trial Protocol Reporting; Randomized Trial Reporting; Reporting Guidelines; Research Ethics; Trial Modifications And Protocol Deviations
Abstract
Rigorous design and transparent reporting of randomized trials and trial protocols are key enablers of open science. Trials can face unavoidable modifications due to new safety or efficacy information, regulatory revisions, changes in the standard of care, and more. Modifications can prompt methodological, ethical, feasibility, and analytical challenges that threaten open science. The COVID pandemic disrupted thousands of trials involving millions of participants. Scientists had no guidance on how to interpret and report those disruptions. CONSERVE (CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances) aims to improve the reporting of trials and trial protocols that undergo important modifications in response to extenuating circumstances. CONSERVE was developed using open science principles, led by a global panel of 37 trial investigators, methodologists, patient representatives, ethicists, funders, regulators, and journal editors. Our protocol was published on the Open Science Framework, involving a literature review, consensus-based panelist meetings using a modified Delphi process, and a global survey of trial stakeholders. The literature review yielded 38 relevant documents, but no generalizable guidance for reporting unanticipated modifications to trials and protocols. The panel used these findings to develop a consensus guideline. The global survey drew 198 respondents in 34 countries, of whom 90% understood the concept definitions and 85.4% could use the implementation tool. Feedback from survey respondents was used to finalize the guideline. CONSERVE was immediately publicly available in June 2021 through JAMA and the EQUATOR Network. CONSERVE offers tools and checklists to support transparent and rigorous reporting when trials and trial protocols face important modifications to the intended study. The panel is investigating the impacts of the CONSERVE 2021 Statement and the quality of trial reporting during the COVID pandemic.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Orkin, Aaron M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $25,000~ $0~